Other Desmoid Tumor Research Worldwide - Desmoid Tumor Research Foundation
Menu

Posters, Abstracts & Presentations

DTRF encourages researchers to send us summaries about their work with desmoid tumors. Those interested should contact us with this information.

View DTRF-funded studies here.

2016 ASCO Annual Meeting

Abstracts

  • Geraldine Helen O’Sullivan Coyne, Shivaani Kummar, Khanh Tu Do, Peter L. Choyke, Baris Turkbey, Eric Polley, Yvonne Horneffer, Lamin Juwara, Rasa J Vilimas, Robert S. Meehan, Lee J. Helman, James H. Doroshow, Alice P. Chen; Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Center/Brigham and Women’s Hospital, Boston, MA; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; Mayo Clinic, Rochester, MN; Leidos BioMedical Research, Inc, Bethesda, MD; Early Clinical Trials Development Program, DCTD, NCI, Bethesda, MD; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD; Early Clinical Trials Development Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

  • Angela Pang, Daniela Venancio Gouveia Macedo, Mariana Carbini, Robert G. Maki; Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY; Oncology Division, Hospital de Santa Maria – CHLN, Lisbon, Portugal; Tisch Cancer Insitute, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY

Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.”

  • Olivier Mir, Chahinez Rahal, Françoise Rimareix, Julien Adam, Philippe Terrier, Julien Domont, Sarah Dumont, Arslane Skander Rahal, Andrea Cavalcanti, Isabelle Sourrouille, Nicolas Leymarie, Charles Court, Gilles Missenard, Leila Haddag-Miliani, Charles Honoré, Axel Le Cesne; Gustave Roussy Cancer Campus, Department of Medical Oncology, Villejuif, France; Gustave Roussy Cancer Campus, Villejuif, France; Department of Biopathology, Gustave Roussy Cancer Center, Villejuif, France

Efficacy of oral vinorelbine in advanced/progressive desmoid tumours: An updated retrospective study in 50 patients.

  • Nuria Kotecki, Armelle Renaud, Mariem Ben Haj Amor, Anne-Sophie Thomassin Defachelles, Thomas Ryckewaert, Vincent Gamblin, Yves Marie Robin, Sophie Taieb, Nicolas Penel; Oscar Lambret Center, Lille, France; Centre Oscar Lambret, Lille, France

Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)?

  • Rodrigo Ramella Munhoz, Robert A Lefkowitz, Deborah Kuk, Mark Andrew Dickson, Sandra P. D’Angelo, Mary Louise Keohan, Ping Chi, Aimee Marie Crago, Robert G. Maki, Gary K. Schwartz, Li-Xuan Qin, William D. Tap, Mrinal M. Gounder; Hospital Sírio Libanês, São Paulo, Brazil; Memorial Sloan Kettering Cancer Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Columbia University Medical Center – New York Presbyterian Hospital, New York, NY

Efficacy of sorafenib in patients with desmoid-type fibromatosis.

  • Sarmen Sarkissian, John P. Fruehauf; University of California, Irvine, Orange, CA; UCI Comprehensive Cancer Center, Orange, CA

Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

Posters

  • Rodrigo Ramella Munhoz, Robert A Lefkowitz, Deborah Kuk, Mark Andrew Dickson, Sandra P. D’Angelo, Mary Louise Keohan, Ping Chi, Aimee Marie Crago, Robert G. Maki, Gary K. Schwartz, Li-Xuan Qin, William D. Tap, Mrinal M. Gounder; Hospital Sírio Libanês, São Paulo, Brazil; Memorial Sloan Kettering Cancer Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Columbia University Medical Center – New York Presbyterian Hospital, New York, NY

Efficacy of sorafenib in patients with desmoid-type fibromatosis.”

  • Geraldine Helen O’Sullivan Coyne, Shivaani Kummar, Khanh Tu Do, Peter L. Choyke, Baris Turkbey, Eric Polley, Yvonne Horneffer, Lamin Juwara, Rasa J Vilimas, Robert S. Meehan, Lee J. Helman, James H. Doroshow, Alice P. Chen; Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Center/Brigham and Women’s Hospital, Boston, MA; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; Mayo Clinic, Rochester, MN; Leidos BioMedical Research, Inc, Bethesda, MD; Early Clinical Trials Development Program, DCTD, NCI, Bethesda, MD; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD; Early Clinical Trials Development Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

2016 DTRF Research Workshop Abstracts & Presentations

Abstracts

  • Benjamin Alman, MD, Department Chair, Orthopedic Surgery, Duke University, “Introduction and Report on Collaboration for a Cure project.”

 

 

 

 

  • Mrinal Gounder, MD, Assistant Professor and Medical Oncologist, Memorial Sloan Kettering Cancer Center, “Development of PRO tool in desmoid tumors.”

 

 

 

 

  • Matt van de Rijn, MD, PhD, Professor, Department of Pathology, Stanford University Medical Center, “Gene expression profiling of desmoid tumors.”

 

 

  • Lara Sullivan, MD, MBA, Vice President, Pfizer CURES, Pfizer, Inc., “Update on clinical trials on Pfizer compound/ a potential new treatment.”

 

 

 

 

2016 CTOS Meeting

2016 DTRF Patient Meeting Abstracts & Presentations

Raffi Avedian, MD, The Stanford University Medical Center.

 

Geraldine O’Sullivan Coyne, MD, PhD, NCI- NIH.

 

Benjamin Alman, MD, Duke University.

 

Kris Vleminckx, PhD, Ghent University.

  • Abstract: “Fishing for New Therapeutic Targets in the Frog Pond.”

 

Raphael E. Pollock, MD, PhD, Ohio State University Comprehensive Cancer Center. 

 

Kelly Mercier, PhD, RTI International.

 

Sunil Sharma, MD, University of Utah School of Medicine, Expert in Oncology Drug Development.

 

Ian Bier, ND, PhD, LAc, FABNO, Human Nature Natural Health.

 

Secili DeStefano, PT, DPT, OCS, Bodies in Motion Physical Therapy.

Presentation: “Optimizing Movement to Improve the Human Experience.”

Miscellaneous

Dr. Bernd Kasper of Mannheim University Medical Center

  • Brief video followup on “Clinical and translational research results of a phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors- A study of the German Interdisciplinary Sarcoma Group (GISG- 01)”

2015 CTOS Meeting

Jacob Bickels, MD, Orthopaedic Oncology, Sourasky Medical Center, Israel

Poster: “Aminolevulinic acid photoablation of fibrotic soft-tissue tumors: preliminary report of 24 patients.”

Chiara Colombo, MD, Surgical Oncology, Fondazione IRCCS Istituto Tumori di Milano

Poster: “Gene expression analysis identifies a potential role of immune system in CTNNB1 mutated desmoid tumors.”

Amanda Kirane, MD, Surgery, Memorial Sloan Kettering Cancer Center

Poster: “Progression of desmoid-type fibromatosis during active observation is associated with tumor size.”

Poster: “Molecular characterization of desmoid tumors.”

2015 DTRF Patient Meeting Presentations

Benjamin Alman, MD, Duke University

Presentation: “Collaboration for a cure: What we’ve learned so far”

Aimee Crago, MD, PhD, Memorial Sloan Kettering Cancer Center

Presentation: “Personalizing management of desmoid tumors”

Kishore Iyer, FRCS, FACS, Mount Sinai Hospital

Presentation: “Challenging Conventional Limits of Inoperability in Abdominal Desmoids and Sarcomas”

Robert Lefkowitz, MD, Memorial Sloan Kettering Cancer Center

Presentation: “MR Imaging of Desmoid Tumors”

Bernd Kasper, MD, PhD, Mannheim University Medical Center

Presentation: “The European Experience”

Jean Paty, PhD, Principle, Advisory Services, Quintiles

Presentation: DTRF’s PRO Development Study

2015 DTRF Research Workshop Abstracts & Presentations

  • Mushriq Al-Jazrawe, University of Toronto
    • Abstract: “Single cell-derived clonal analysis of desmoid tumors”
    • Presentation: “Single cell-derived clonal analysis of desmoid tumors”

 

  • Radhika Atit, PhD, Case Western University
    • Presentation: “Sustained β-catenin activation in dermal fibroblasts promotes fibrosis by regulating cell proliferation and extracellular matrix protein-coding genes”

 

  • Benjamin Alman, MD, Duke University
    • Presentation: “From the bedside to the bench and the back again”

 

  • Danielle Braggio, PhD, Ohio State University
    • Abstract: “Reactivation of apoptosis as a potential therapeutic target for desmoid tumors with CTNNB1 S45F mutation”
    • Presentation: “Reactivation of apoptosis as a potential therapeutic target for desmoid tumors with CTNNB1 S45F mutation”
    • Abstract: “Targeting the notch pathway: a potential therapeutic approach for desmoid tumors”
    • Presentation: “Desmoid Tumors Harboring S45F B-catenin Mutation are Highly Resistant to Apoptosis”

 

  • Alice Chen, MD, National Institutes of Health/ National Cancer Institute
    • Abstract: “A Phase II trial of PF-03084014 in adults with Desmoid tumors/Aggressive Fibromatosis”
    • Presentation: “A Phase II trial of PF-03084014 in adults with Desmoid tumors/Aggressive Fibromatosis”

 

  • Meredith Chuk, MD, Food and Drug Administration
    • Presentation: “FDA Draft Guidance- Rare Diseases: Common Issues in Drug Development”

 

  • Aimee Crago, MD, PhD, Memorial Sloan Kettering Cancer Center
    • Abstract: “Oncogenic effects of activated beta-catenin in desmoid fibromatosis”
    • Abstract: “Whole Exome Sequencing and Integrated Genomic Analysis of ‘Wild-Type’ Desmoids Identifies Potential Drivers of Tumor Initiation”

 

  • Alessandro Datti, PhD, SMART Laboratory for High Throughput Screening Programs
    • Presentation: “Introduction to drug repositioning towards novel therapeutics for desmoid tumors”

 

  • Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center
    • Article: “Notch inhibition in desmoids: Sure it works in practice, but does it work in theory?”

 

  • Katherine Hartley, MD, Vanderbilt University
    • Poster: “Image-guided cryoablation for desmoid tumors: successes, challenges and lessons learned”
    • Poster: “16α-[18F]-fluoro-17ß-estradiol (18F-FES) PET/CT Imaging of Estrogen Receptor Activity in Desmoid Tumors”

 

  • Bernd Kasper, MD, PhD, Mannheim University Medical Center
    • Presentation: “Clinical and translational research results of a phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors- A study of the German Interdisciplinary Sarcoma Group (GISG- 01)”

 

  • Kelly Mercier, PhD, RTI International
    • Abstract: “Metabolomics: Towards a Better Understanding of Desmoid Tumors”
    • Presentation: “Metabolomics: Towards a Better Understanding of Desmoid Tumors”

 

  • Yoshihiro Nishida, MD, PhD, Nagoya University
    • Abstract: “Planned simple resection for selected patients with extra-peritoneal desmoid tumors”
    • Presentation: “Planned simple resection for selected patients with extra-peritoneal desmoid tumors”

 

  • Raphael Pollock, MD, PhD, Ohio State University
    • Article: “Targeting the notch pathway: A potential therapeutic approach to desmoid tumors”

 

  • Ty Subhawong, University of Miami Miller School of Medicine
    • Presentation: “MRI Features of Response in Systemic Therapy for Aggressive Fibromatosis”

2013 SPAEN Conference

Sylvie Bonvalot, MD, PhD, Institut de Cancerologie- Gustave Roussy

Presentation:  “Management of desmoids”

 

Rick Haas, Netherlands Cancer Institute- Amsterdam

Presentation: “The role of radiotherapy in desmoids”

 

Bernd Kasper, MD, PhD, Mannheim University Medical Center

Presentation: “Update on systemic treatment options and clinical trials in desmoids”

 

Daniela Segat, PhD, B.I.R.D Foundation

Presentation:  “Unraveling the desmoid-type fibromatosis at the cellular level: GSK- 3beta, a new piece of the puzzle”

Miscellaneous

Sumer Sethi, Sumer’s Radiology Blog, 2009- CTs versus MRIs on desmoid tumors

  TOP